,Outcomes,Arm 1,Arm 2
0,intervention,topotecan,paclitaxel
1,median survival,63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ),53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored )
